Cargando…
Cross-over comparison and new chemotherapy regimens in metastatic pancreatic cancer
Despite decades of research, pancreatic ductal adenocarcinoma (PDAC) is still one of the most lethal malignant diseases with a devastating 5‑year overall survival of only 4–5%. Indeed, long-term survival was not affected by the introduction of new systemic cytotoxic chemotherapies which remain the k...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Vienna
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5605578/ https://www.ncbi.nlm.nih.gov/pubmed/28989542 http://dx.doi.org/10.1007/s12254-017-0352-2 |